Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
about
Finasteride for benign prostatic hyperplasiaKorean clinical practice guideline for benign prostatic hyperplasiaTestosterone and benign prostatic hyperplasiaClinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia.Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male miceLong-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trialPersonalized medicine for the management of benign prostatic hyperplasiaAssociations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomesAndrogens and estrogens in benign prostatic hyperplasia: past, present and future.Current trends in the management of difficult urinary catheterizations.Testosterone replacement therapy and voiding dysfunction.CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway.Emerging drugs for the treatment of benign prostatic obstruction.Testosterone Replacement Therapy on the Natural History of Prostate Disease.Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia.NAD(P)H-quinone oxidoreductase 1 silencing aggravates hormone-induced prostatic hyperplasia in mice.How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).Deregulation of ATG9A by impaired AR signaling induces autophagy in prostate stromal fibroblasts and promotes BPH progression.
P2860
Q24234464-274C00C9-C30A-472E-A860-5FFEF4F7F77BQ26766302-BB52FF34-6BC7-4E14-A3A3-EB214F31B005Q26863719-6DEEAE29-A057-41E3-86ED-6699EEAD0794Q30408224-0BF0F102-B378-46B8-9DF9-8679ED4513F4Q30525673-1BDCF92A-6691-4AB4-A217-ECEB0FAD9255Q33824628-BA803AB0-5BC2-47A3-AF51-23BAE16347F7Q34084593-71CB9F52-3B58-4E2D-9EA4-B6A1B8F88E49Q34760359-E2729AC7-4A60-455C-9C65-E832C6BA664FQ35231660-A9D86774-5B8F-4846-8A6B-D33193F4C87BQ36564151-AD8374D6-94AC-476A-914F-EF3020348F40Q37531050-5B50D1F4-C11E-4E74-A3DE-0846DC5AA918Q37652222-F1E76F76-D9F1-47A1-B57E-274691425B73Q37743490-A393D82D-63CD-42F3-B765-5D91932A657FQ38528388-9EF52360-34D2-49F5-A88C-8C2B4FE76DFEQ40000585-BE61CD54-5014-4175-9E0C-BDB6549AB632Q47433004-4C907125-5606-408E-B9C6-46342E18DF8CQ48081848-388609B1-2FC7-40C4-93CE-8F49825F3707Q48721867-2FD34366-AEBB-4E2B-AD16-F35694B8DA9FQ55040819-8AE66FE8-B518-4EA0-86A5-5317C7B90E28
P2860
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@en
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@nl
type
label
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@en
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@nl
prefLabel
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@en
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@nl
P2093
P1476
Long-term treatment with finas ...... n enrolled in the MTOPS trial.
@en
P2093
Alan G Meehan
Claus G Roehrborn
Jeannette Y Lee
Jennifer Rotonda
John D McConnell
John W Kusek
Leroy M Nyberg
Medical Therapy of Prostatic Symptoms Research Group
Shailaja Surynawanshi
Steven A Kaplan
P304
1030-2; discussion 1032-3
P356
10.1016/J.JURO.2008.05.004
P407
P577
2008-07-17T00:00:00Z